Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused ReviewBIOMEDICINESIF3.92021-12-104OAAI
Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific AntibodyCELLSIF5.22020-10-0210OAAI
A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to ImmunotherapyFRONTIERS IN IMMUNOLOGYIF5.92019-10-258OAAI
Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principleJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHIF12.82019-07-2314OAAI
Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseasesJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHIF12.82019-03-1290OAAI
Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cellsMABSIF7.32018-07-1110OAAI
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigenIMMUNOLOGY LETTERSIF2.82015-11-0112PREAI
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancerEUROPEAN JOURNAL OF CANCERIF7.12013-06-0152PREAI
Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infectionJOURNAL OF TRANSLATIONAL MEDICINEIF7.52009-11-285OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向